Skip to main content

Cognition trajectory in Duchenne muscular dystrophy

Abstract

Background

Duchenne muscular dystrophy (DMD) is an X-linked recessive disease brought on by genetic changes that alter the dystrophin (DYS) protein. There has been growing evidence that children with DMD have been at higher risk of developing symptoms of neurodevelopmental disorders. We aimed at defining the cognitive difficulties and their categories in patients with DMD, compared to healthy controls, and assessing their relation with the functional severity. This work was a multi-center, observational, case–control study conducted on DMD patients. Age and sex-matched healthy subjects with no neurologic, psychiatric, or medical comorbidities were included as normal controls.

Results

There was a statistically significant difference in cognitive patterns between the studied groups. We have observed a significant relationship between cognitive difficulties and functional severity assessment in our patients. There was a statistically significant difference between the studied cases regarding basic characteristics and correlation between cognitive functions and demographic data.

Conclusions

The decline in cognitive functions in DMD patients compared to healthy controls was established. Education was the most affected domain in patients, with more speech delay and dropping out of school. Therefore, it was recommended to establish cognitive screening as a routine in the evaluation and follow-up of DMD children.

Significance statement

The results of our research bring attention to the importance of early screening and support and the need for continued follow-up of children with DMD. Special attention should be given to children with educational and cognitive difficulties, because they are more likely to receive support and health care services.

Background

It is currently unknown how many elements of cognitive function are affected by neuromuscular disorders, even though these diseases present a wide variety of clinical symptoms [1]. Neuromuscular diseases are known to predominantly affect a patient’s motor function, but they can also have significant effects on cognitive function [2]. Three large diverse groups of neuromuscular disorders that have been associated with cognitive abnormalities include motor neuron illnesses, muscular dystrophies, and mitochondrial disorders [3, 4]. Cognitive impairment is a recognized feature of around one-third of DMD patients. One early sign of this condition is delay in language or global development [5]. The dystrophin protein (DYS) is essential to the structural organization of the central nervous system (CNS). It is responsible for organizing gamma-amino butyric acid type A (GABAA) receptors, which are normally expressed at the postsynaptic membrane in inhibitory synapses of brain areas linked to emotional and cognitive behavior, such as the cerebellum, hippocampus, amygdale, and sensory cortices [6]. Though its exact role in the nervous system is unknown, dystrophin is generally present in brain regions involved in higher order function. The dystrophin gene's protein products are far more varied in brain tissue, even though the expression of dystrophin in the brain is just 10% of that in muscles. It is made up of shorter proteins, with Dp71 being the main one expressed in the brain, and the whole protein is Dp427. The presence of Dp71 close to the perivascular astrocyte end foot suggests that it may have a role in the operation of the blood–brain barrier and the possible entrance of inflammatory substances from the peripheral nervous system into the brain. Dp427 is only found in neurons and certain brain regions in the central nervous system (CNS), such as the neocortex, cerebellar Purkinje cells, amygdale, and hippocampal areas. Dp47's interaction with DGC is essential for the formation and maintenance of new synaptic connections [2]. Furthermore, intellectual impairment has been associated with the disruption of many dystrophin isoforms, suggesting the critical need for these isoforms for appropriate brain function [7]. There is growing evidence that children with DMD are more likely than the general pediatric population to exhibit signs of neurodevelopmental problems, even though neuromuscular illnesses have a wide range of clinical presentations. Even still, little is known about how these illnesses affect different aspects of cognitive function. Cognitive impairment is a known feature of around one-third of DMD patients. One of the illness's initial symptoms may be delay in linguistic or global development [8]. Given this, the current study is aimed at describing the cognitive difficulties linked to DMD relative to healthy controls, and ascertaining the relationship between these difficulties and the functional severity in our studied patients.

Methods

Over 3 months, 40 DMD patients were recruited from the neuropsychiatry departments at Aswan university and the October 6 university hospitals for a multi-center, observational, case–control research. A group of 40 participants who were similar in age and gender and who did not exhibit any medical, mental, or neurological comorbidities were included as controls. Only male sex was studied. The Ethics Committee of our University in Egypt’s Faculty of Medicine gave its approval to the protocol (IRB: 698/12/22). All participants gave their signed, informed consent after being told about the purpose and design of the study. Individuals with a clinical diagnosis of DMD, validated by genetic testing, were included. Individuals who fulfilled the study’s eligibility criteria included those who were over 8 but under 18 years, as well as those whose Multiplex ligation-dependent probe amplification (MLPA) test indicated DMD gene deletion or duplication. One patient, who was not even 8 years, had normal multiplex ligation-dependent probe amplification (MLPA), was severely intellectually disabled, had respiratory embarrassment, used respiratory assistant machines, had cardiac complications, and had a medical or surgical history of any condition that may have an impact on neurocognitive functioning (such as a brain tumor or significant head injury). It was necessary to establish a minimum sample size of 80 individuals, with an error probability of 0.05% and 95% power on a two-tailed test (42 cases of DMD and 42 controls).

A single very skilled neurologist assessed each patient clinically. Age, sex, family history (for consanguineous marriage, the existence of comparable illnesses, any neuropsychiatric problems in the family, and developmental history), and a complete medical and neurological history and examination were conducted. The following scales were used to complete the motor assessment: the Medical Research Council (MRC) Scale, which has a score ranging from 0 (no contraction at all) to 5 (normal), is one tool used to quantify motor function severity and progression [9]. Another tool is the Motor Function Quantify Test (MFM-32). The range of a total score is 0–96 [10]. The third tool is the 17-item North Star Ambulatory Assessment (NSAA) rating scale, which has a 0–2 rating range. A total score of 0 indicates total non-ambulation, whereas a score of 34 indicates full independence [11]. The Wechsler Intelligence Scale for Children, Fourth Edition (WISC-IV), which is a standardized test that yields a full-scale intelligence quotient (FSIQ), or overall intellectual ability, and index scores that measure various domains, such as verbal intelligence, non-verbal intelligence, working memory, and processing speed, was used to conduct cognitive assessment. These instruments are widely recognized as reference points for developmental and cognitive assessment in developmental age [12]. The verbal comprehension index (VCI), processing speed index (PSI), working memory index (WMI), and perceptual reasoning index (PRI) are the sub-indices of the WISC-IV. The Benton Visual Retention Test (BVRT) is a test that evaluates visual memory and perception, and is given one at a time [13]. The corresponding author alone was in charge of the data and has unrestricted access thereto.

The computer was given data, and IBM SPSS software package version 20.0 was used for analysis. (IBM Corp., Armonk, NY, USA) numbers and percentages were used to describe the qualitative data. The distribution's normality was confirmed using the Kolmogorov–Smirnov test. The terms range (minimum and maximum), mean, standard deviation, median, and interquartile range (IQR) were used to characterize quantitative data. The results were deemed significant at the 5% level. The Chi-square test was used to compare several groups based on categorical characteristics. For regularly distributed quantitative variables, the student T test was employed to compare the two groups under study. For group correlations, Spearman's rank correlation coefficient was employed. Based on the examination of the ROC curves, the optimal cutoff was determined by determining the biomarker value that yielded the best combination of sensitivity and specificity, or the value that maximized the sum of the sensitivity and specificity. The Youden index was used to conduct the ROC curve study.

Results

Table 1 displays the basic characteristics of the DMD patients under study.

Table 1 Basic characteristics of studied patients with DMD

We have found high statistically significant differences in cognitive patterns between the examined groups, as displayed in Table 2 and Fig. 1.

Table 2 Cognitive patterns of the studied cases and controls
Fig. 1
figure 1

Comparison between the studied cases according to, WISC-IV Scales

Table 3 demonstrates the lack of association between demographic information and cognitive skills. The cognitive patterns (measured by Wechsler scales, BVRT accurate, and full-scale intelligence) and motor assessment scales (MRC, MFM32, and NSAA) displayed a strong positive link in the patients under study.

Table 3 Correlation between cognitive functions and demographic data in studied cases

Table 4 illustrates the strong negative associations between BVRT error and motor assessment scores.

Table 4 Correlation between cognitive functions and functional assessment

Table 5 and Fig. 2 demonstrate that, an AUC of 1, degree of sensitivity of 100%, specificity of 100%, the cutoffs for VCI, WMI, and FSIQ at 101.5, 96.5, and 101, respectively, could be used to differentiate between cases and controls.

Table 5 ROC curve analysis for the use of cognitive functions to discriminate between cases and controls
Fig. 2
figure 2

ROC curve analysis for the use of cognitive functions to discriminate between cases and control. VCI verbal comprehension index, PRI perceptual reasoning index, WMI working memory index, PSI processing speed index, BVRT Benton Visual Retention Test, FSIQ Full-scale intelligence Quotient

Discussion

Duchenne muscular dystrophy (DMD), one of the most prevalent genetic diseases, affects around 1 in 3600–6000 live male births. Non-progressive cognitive deficits and slow muscular degeneration are the condition's hallmarks. Brain comorbidities may affect a person with DMD's family more severely than mobility. Moreover, DYS is essential for the central nervous system's structural organization [8].

Nearly, half of DMD patients were chronically wheelchair dependent, according to Bendixen and colleagues who reported substantially lower engagement levels in physical activities in DMD, demonstrating that growing muscle degradation is a feature of the condition [14].

A unique pattern of schooling was more prominent among our patients, according to Sayed and colleagues, who found a statistically significant difference regarding school attendance, where home-schooling and stopping school were visible in the DMD boys [6]. On the other hand, 94.7% of boys with DMD attended school, according to LĂ³pez–HernĂ¡ndez’s study. The fact that our domestic educational institutions are unprepared to meet the demands of students with this kind of handicap might help to explain this [15]. Interestingly, we found a sizable proportion of DMD patients with a positive family history of neurological conditions. These results are in line with those of Sayed and colleagues who reported cases of distinct paternal consanguinity [6].

We demonstrated that our patients had significantly lower scores on the WISC-IV Scales (VCI, PRI, WMI, and PSI), BVRT, and full-scale intelligence quotient (FSIQ) than did the controls, indicating inferior cognitive functioning in DMD compared to the general population. Our results concurred with those of D’Alessandro et al. [5]. Furthermore, Chieffo and his colleagues discovered that IQ appeared to decrease with age and increased muscle weakness in children with DMD, who also had a substantial prevalence of mental disability [16]. Furthermore, compared to the same controls, children with DMD showed statistically significant differences in learning, executive, and memory (short- and long-term) scores [5]. Furthermore, Sayed and colleagues concentrated more on the DMD boys’ comprehension of difficult problems, their capability to provide intelligent responses, their ability to take in, hold onto, and recall information, their verbal expressiveness, and their working memory [6]. Peristeri and colleagues demonstrated deficits in verbal short-term memory and fluency as well as visuospatial long-term memory [17], in addition to a loss in full-scale IQ. According to Vengalil's research, boys with DMD had noticeably lower IQs. It was discovered that the Performance IQ was higher than the Verbal IQ [18]. Since mdx mice lacked dystrophin, cytokines were found in the hippocampus. Furthermore, peripheral tissue and plasma from DMD patients exhibit these cytokines at persistently high levels. Because of their neuromodulatory effects on the hippocampus, important proinflammatory cytokines, such as IL-1, TNF-, and IL-6, have been associated with poorer memory and learning. Thus, there may be a neuroimmune component to the CNS dysfunction in those with dystrophin deficiency [19]. While performance IQ is less compromised, DMD patients often exhibit a cognitive profile with abnormalities, particularly in the areas of verbal working memory and auditory comprehension [18]. Reports state that up to 40% of DMD patients have difficulty with reading. Further evaluations revealed that these individuals also had problems with phonological awareness/processing and short-term verbal memory [18].

The severity of our DMD patients' motor function as determined by the MRC, MFM32, and NSAA was significantly correlated with their cognitive function as determined by the Wechsler scales, BVRT correct, and full-scale intelligence. This suggests that as their muscle weakness worsened, their cognitive function appeared to be deteriorating. The results of Doorenweerd [20] observed that children with DMD who experience motor delay and delayed language milestones in their early years of life will do badly on intelligence tests beyond the age of four and will have a greater degree of cognitive impairment were supporting these findings. Notably, walking delay and cognitive impairment were found to be strongly correlated by Mirski and colleagues if cognitive development was delayed, boys with DMD were three times more likely to have a walking delay [21]. Furthermore, the results of D'Alessandro and colleagues demonstrated a strong association between the overall scores on the North Star Ambulatory Assessment (NSAA) and the WISC-IV FSIQ scores [5].

The main pathophysiological mechanisms causing cognitive impairments in DMD include the involvement of dystrophin in embryonic development, the interaction between genes and non-genetic agents, and the existence of numerous dystrophin isoforms [22]. Several biochemical mechanisms have been linked to the loss of muscle mass (muscle atrophy) and cognitive impairment [23]. These mechanisms include altered myokine synthesis, oxidative stress, inflammation, insulin resistance, aberrant protein buildup, and mitochondrial dysfunction.

Other research has considered the relationship between speech and language ability in DMD patients and cerebellar involvement. Kreis and colleagues reported that a metabolic examination of the patients' cerebellum and temporal–parietal area, which were associated with verbal IQ and short-term memory, showed severe abnormalities in glutamate and N-acetyl compounds in addition to continuous choline deficits. Many brain illnesses are associated with elevated levels of choline-containing substances, which is probably indicative of an unstable increase in membrane turnover caused by either inflammation or quicker cell division. However, the hypothesis that membrane turnover has changed is called into question by the fact that the concentration of choline molecules is consistently increased in DMD [24].

Using ROC analysis, the WISC-IV Scales (VCI, WMI, and FSIQ) were able to differentiate between patients and controls with a high sensitivity of 100% and a specificity of 100% with cutoffs of 101.5, 96.5, and 101, respectively. The WISC-IV score for DMD diagnosis shows a ROC curve with 82% sensitivity, 74% specificity, and 78% accuracy, according to Nardes and colleagues [25].

Conclusion

We have concluded that DMD patients have had worse cognitive and motor functioning, and higher rates of school dropouts than the general population. Therefore, we advise using cognitive screening as a routine component of diagnosing and treating children with DMD. If cognitive deficits are correctly identified and treated, patients with DMD may engage with caretakers more successfully, which might improve care and raise quality of life (QOL).

Availability of data and materials

The corresponding author takes full responsibility for the data, has full access to all of the data, and has the right to publish any and all data separate and apart from any sponsor. This statement was mentioned in the methods section of the research.

Abbreviations

DMD:

Duchenne muscular dystrophy

DYS:

Dystrophin protein

DGC:

Dystrophin–glycoprotein complex

CNS:

Central nervous system

MLPA:

Multiplex ligation-dependent probe amplification

MRC:

Medical Research Council

MFM-32:

Motor Function Measure

NSAA:

North Star Ambulatory Assessment

WISC-IV:

Wechsler Intelligence Scale for Children, Fourth Edition

FSIQ:

Full-scale intelligence Quotient

VCI:

Verbal comprehension index

PRI:

Perceptual reasoning index

WMI:

Working memory index

PSI:

Processing speed index

BVRT:

Benton Visual Retention Test

References

  1. Katz JA, Murphy GS. Anesthetic consideration for neuromuscular diseases. CurrOpinAnesthesiol. 2017;30(3):435–40.

    Google Scholar 

  2. Orsini M, Carolina A, Ferreira AF, de Assis ACD, MagalhĂ£es T, Teixeira S, et al. Cognitive impairment in neuromuscular diseases: A systematic review. Neurol Int. 2018;10(2):7473.

    Article  PubMed  PubMed Central  Google Scholar 

  3. Van Es MA, Hardiman O, Chio A, Al-Chalabi A, Pasterkamp RJ, Veldink JH, et al. Amyotrophic lateral sclerosis. Lancet. 2017;390(10107):2084–98.

    Article  PubMed  Google Scholar 

  4. Wiessner M, Roos A, Munn CJ, Viswanathan R, Whyte T, Cox D, et al. Mutations in INPP5K, encoding a phosphoinositide 5-phosphatase, cause congenital muscular dystrophy with cataracts and mild cognitive impairment. Am J Hum Genet. 2017;100(3):523–36.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  5. D’Alessandro R, Ragusa N, Vacchetti M, Rolle E, Rossi F, Brusa C, et al. Assessing cognitive function in neuromuscular diseases: A pilot study in a sample of children and adolescents. J ClinMed. 2021;10(20):4777.

    Google Scholar 

  6. Sayed MM, Fahmy NA, El Habiby MMM, Elsayed NSE, Bukhari E, Mohamed SMK, et al. Cognitive and neurobehavioral patterns in a sample of Egyptian patients genetically diagnosed with Duchene muscular dystrophy. MECPsych. 2022;29(1):1–9.

    Google Scholar 

  7. Darmahkasih AJ, Rybalsky I, Tian C, Shellenbarger KC, Horn PS, Lambert JT, et al. Neurodevelopmental, behavioral, and emotional symptoms common in Duchene muscular dystrophy. Muscle Nerve. 2020;61(4):466–74.

    Article  PubMed  Google Scholar 

  8. Hellebrekers DM, van Abeelen SA, Catsman CE, van Kuijk SM, Laridon AM, Klinkenberg S, et al. Cognitive and behavioral functioning in two neurogenetic disorders; how different are these aspects in Duchene muscular dystrophy and Neurofibromatosis type 1? PLoS ONE. 2022;17(10): e0275803.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  9. Naqvi U, Sherman AI. Muscle strength grading. StatPearls. https://www.ncbi.nlm.nih.gov/books/NBK430685/. Accessed 17 Feb 2019.

  10. Bérard C, Payan C, Hodgkinson I, Fermanian J, MFM Collaborative Study Group. A motor function measure scale for neuromuscular diseases. Construction and validation study. NeuromusculDisord. 2005;15(7):463–70.

    Google Scholar 

  11. Muntoni F, Guglieri M, Mah JK, Wagner KR, Brandsema JF, Butterfield RJ, et al. Novel approaches to analysis of the North Star Ambulatory Assessment (NSAA) in Duchene muscular dystrophy (DMD): Observations from a phase 2 trial. PLoS ONE. 2022;17(8): e0272858.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  12. Wechsler D. Wechsler intelligence scale for children. 4th ed. San Antonia, TX: PsychCorp; 2003.

    Google Scholar 

  13. Benton AL. A visual retention test for clinical use. Arch Neurol Psychiatr. 1945;54(3):212–6.

    Article  CAS  Google Scholar 

  14. Bendixen RM, Senesac C, Lott DJ, Vandenborne K. Participation and quality of life in children with Duchene muscular dystrophy using the International Classification of Functioning, Disability, and Health. Health Qual Life Outcomes. 2012;10(1):1–9.

    Article  Google Scholar 

  15. LĂ³pez-HernĂ¡ndez LB, Gomez-Diaz B, Escobar-Cedillo RE, Gama-Moreno O, Camacho-Molina A, Soto-Valdes DM, et al. Duchene muscular dystrophy in a developing country: challenges in management and genetic counseling. Genet Couns. 2014;25(2):129.

    PubMed  Google Scholar 

  16. Chieffo DPR, Moriconi F, Pane M, et al. A longitudinal follow-up study of intellectual function in Duchene muscular dystrophy over age: is it really stable? J Clin Med. 2023;12(2):403.

    Article  PubMed  PubMed Central  Google Scholar 

  17. Peristeri E, Aloizou A, Keramida P, Tsouris Z, Siokas V, Mentis A, et al. Cognitive deficits in myopathies. Int J Mol Sci. 2020;21:3795.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  18. Vengalil S, Preethish-Kumar V, Polavarapu K, Mahadevappa M, Sekar D, Purushottam M, et al. Duchene muscular dystrophy and Becker muscular dystrophy confirmed by multiplex ligation-dependent probe amplification: genotype–phenotype correlation in a large cohort. J Clin Neurol. 2017;13(1):91–7.

    Article  PubMed  Google Scholar 

  19. Rae MG, O’Malley D. Cognitive dysfunction in Duchene muscular dystrophy: a possible role for neuromodulatory immune molecules. JNP. 2016;116(3):1304–15.

    CAS  PubMed  PubMed Central  Google Scholar 

  20. Doorenweerd N. Combining genetics, neuropsychology and neuroimaging to improve understanding of brain involvement in Duchene muscular dystrophy—a narrative review. Neuromuscul Disord. 2020;30(6):437–42.

    Article  PubMed  Google Scholar 

  21. Mirski KT, Crawford TO. Motor and cognitive delay in Duchene muscular dystrophy: implication for early diagnosis. J Pediatr. 2014;165(5):1008–10.

    Article  PubMed  Google Scholar 

  22. Mohamadian M, Rastegar M, Pasamanesh N, Ghadiri A, Ghandil P, Naseri M. Clinical and molecular spectrum of muscular dystrophies (MDs) with intellectual disability (ID): a comprehensive overview. J MolNeurosci. 2022;1:1–5.

    Google Scholar 

  23. Oudbier SJ, Goh J, Looijaard SM, Reijnierse EM, Meskers CG, Maier AB. Pathophysiological mechanisms explaining the association between low skeletal muscle mass and cognitive function. J GerontolABiolSci Med Sci. 2022;77(10):1959–68.

    Article  CAS  Google Scholar 

  24. Kreis R, Wingeier K, Vermathen P, Giger E, Joncourt F, Zwygart K, et al. Brain metabolite composition in relation to cognitive function and dystrophin mutations in boys with Duchene muscular dystrophy. NMR Biomed. 2011;24(3):253–62.

    Article  CAS  PubMed  Google Scholar 

  25. Nardes F, AraĂºjo AP, Ribeiro MG, Bittar M, Gomes HF. The mini-mental state examination (MMSE) as a cognitive screening tool in Duchene muscular dystrophy. Ann Child Neurol. 2020;28(2):57–65.

    Article  Google Scholar 

Download references

Acknowledgements

We thank all subjects for their participation and acceptance to be studied in our work.

Funding

Non-financial associations that may be relevant to the submitted manuscript.

Author information

Authors and Affiliations

Authors

Contributions

T AA did the acquisition, analysis, interpretation of data and as well as contributing with most of the writing and review of the manuscript. A SH applied the cognitive tests used. A S did the acquisition of cases. K RM did the analysis, and review it. All authors read, agreed and approved the final manuscript.

Corresponding author

Correspondence to Abeer A. Tony.

Ethics declarations

Ethics approval and consent for publication

The Institutional Ethics Committee, Faculty of Medicine, Aswan University granted approval for the study (IRB: Asw. U./698/12/22). The goals, procedures, and risk/benefit analysis of the research were fully disclosed to all patient parents. Written permission was obtained from each subject's parents or legal guardian upon admission to the research, in the event that parents were unable to participate. The Declaration of Helsinki was followed in conducting the study.

Consent for publication

Not applicable.

Competing of interests

The authors declare that they have no competing interests.

Additional information

Publisher's Note

Springer Nature remains neutral with regard to jurisdictional claims in published maps and institutional affiliations.

Rights and permissions

Open Access This article is licensed under a Creative Commons Attribution 4.0 International License, which permits use, sharing, adaptation, distribution and reproduction in any medium or format, as long as you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons licence, and indicate if changes were made. The images or other third party material in this article are included in the article's Creative Commons licence, unless indicated otherwise in a credit line to the material. If material is not included in the article's Creative Commons licence and your intended use is not permitted by statutory regulation or exceeds the permitted use, you will need to obtain permission directly from the copyright holder. To view a copy of this licence, visit http://creativecommons.org/licenses/by/4.0/.

Reprints and permissions

About this article

Check for updates. Verify currency and authenticity via CrossMark

Cite this article

Tony, A.A., Abdelrashid, S., Ahmed, H.S. et al. Cognition trajectory in Duchenne muscular dystrophy. Egypt J Neurol Psychiatry Neurosurg 60, 80 (2024). https://doi.org/10.1186/s41983-024-00842-8

Download citation

  • Received:

  • Accepted:

  • Published:

  • DOI: https://doi.org/10.1186/s41983-024-00842-8

Keywords